Venus Concept Announces Second Quarter 2025 Financial Results
VEROTORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2025.
On June 5, 2025, Venus Concept Entered Into A Unit Purchase Agreement With Meta Robotics And MHG Co. Pursuant To Which The Company Agreed To Sell The Venus Hair Business To Meta Healthcare Group In An All-Cash Transaction Valued At $20M
VEROVenus Concept Stock Is Soaring On Friday - Here's Why
VEROVenus Concept Inc. (VERO) traded higher on Friday after entering into agreements to purchase and sell shares at $2.65 per share, expecting $1.15 million in proceeds.
Venus Concept Announces $1.15M Registered Direct Offering Of Common Stock At $2.65/Share And Concurrent Private Placement Of Unregistered Warrants For Up To $2.3M In Potential Proceeds
VEROCORRECTION: Venus Concept shares are trading higher.
VEROVenus Concept To Sell Venus Hair Business To Meta Healthcare For $20M In All-Cash Deal To Boost Balance Sheet And Growth Plans
VEROVenus Concept And Subsidiaries Reached Consent Agreement With Madryn Health Partners, Waiving Certain Liquidity Requirements To Apply June 8 Cash Interest Payment To Principal Balance Through June 30, 2025.
VEROVenus Concept Q1 Adj. EPS $(15.96) Misses $(14.08) Estimate, Sales $13.64M Miss $13.99M Estimate
VEROVenus Concept Announces Closing Of Registered Direct Offering At $4.06 Per Share. Gross Proceeds ~$1.57M
VEROVenus Concept Announces $1.5M Registered Direct Offering Of Common Stock Priced At-The-Market Under Nasdaq Rules; 386,700 Shares At Purchase Price Of $4.06 Per Share
VEROVenus Concept Enters Into Definitive Agreements For The Purchase And Sale Of 328,573 Shares Of Common Stock At A Purchase Price Of $3.50 Per Share In A Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
VEROVenus Concept Shares Tripled On Wednesday: Here's What Happened
VEROVenus Concept Inc. (NASDAQ: VERO) shares traded higher on Wednesday after the company secured $23.24 million in bridge financing from Madryn Health Partners.
Venus Concept Secures Bridge Financing Of Up To $23.24M From Madryn Health Partners With Multiple Drawdowns, Including Drawdown Under The Loan And Security Agreement Of $2M On April 4, 2025, To Support General Working Capital And Ongoing Operations
VEROVenus Concept Has Received A Decision To Grant European Patent Number EP3542745 Titled DEVICE FOR FRACTIONAL RF TREATMENT OF THE SKIN (TO IMPROVE APPEARANCE)
VEROVenus Concept Exchanges $11M Of Its Subordinated Convertible Notes Held By Affiliates Of Madryn For 379,311 Shares Of Its Series Y Preferred Stock
VEROVenus Concept Q4 2024 GAAP EPS $(11.23) Misses $(10.01) Estimate, Sales $15.77M Miss $17.00M Estimate
VEROEarnings Outlook For Venus Concept
VEROVenus Concept Shares Halted On Circuit Breaker To The Downside, Stock Now Down -23.1%
VEROTrading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
VEROTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
VEROVenus Concept Will Effect A 1-for-11 Reverse Stock Split, Effective At 5:00 P.M. Eastern Standard Time On March 3
VEROVenus Concept's Return On Capital Employed Overview
VEROVenus Concept (NASDAQ:VERO) brought in sales totaling $27.27 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 21.72%, resulting in a loss of $10.51 million.
Venus Concept Gets FDA 510(k) Clearance for Venus BlissMAX with expanded indication
VEROVenus Concept Inc. (NASDAQ: VERO) received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the Venus BlissMAX device with an expanded indication for use in new areas of the body and an increase in RF energy output.
Venus Concept Receives New FDA 510 Clearance For Venus Blissmax
VERO